Cwm LLC raised its stake in Cambrex Co. (NYSE:CBM) by 22.1% in the fourth quarter, HoldingsChannel.com reports. The fund owned 42,120 shares of the biotechnology company’s stock after purchasing an additional 7,612 shares during the period. Cwm LLC’s holdings in Cambrex were worth $1,590,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently made changes to their positions in CBM. Franklin Resources Inc. lifted its holdings in Cambrex by 117.6% in the third quarter. Franklin Resources Inc. now owns 503,600 shares of the biotechnology company’s stock valued at $34,446,000 after acquiring an additional 272,117 shares during the period. Acadian Asset Management LLC lifted its holdings in Cambrex by 104.3% in the third quarter. Acadian Asset Management LLC now owns 483,763 shares of the biotechnology company’s stock valued at $33,090,000 after acquiring an additional 247,016 shares during the period. Copper Rock Capital Partners LLC lifted its holdings in Cambrex by 161.4% in the fourth quarter. Copper Rock Capital Partners LLC now owns 391,490 shares of the biotechnology company’s stock valued at $14,771,000 after acquiring an additional 241,749 shares during the period. William Blair Investment Management LLC raised its stake in shares of Cambrex by 9.9% during the 3rd quarter. William Blair Investment Management LLC now owns 2,530,397 shares of the biotechnology company’s stock worth $173,079,000 after buying an additional 228,059 shares during the period. Finally, Castleark Management LLC acquired a new position in shares of Cambrex during the 3rd quarter worth approximately $12,093,000.

Shares of CBM stock opened at $44.40 on Tuesday. The company has a debt-to-equity ratio of 0.49, a current ratio of 4.54 and a quick ratio of 3.41. The company has a market cap of $1.47 billion, a PE ratio of 11.02, a price-to-earnings-growth ratio of 1.48 and a beta of 2.40. Cambrex Co. has a 1-year low of $35.98 and a 1-year high of $69.43.

Cambrex (NYSE:CBM) last announced its earnings results on Thursday, November 8th. The biotechnology company reported $0.49 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.59 by ($0.10). The business had revenue of $104.62 million for the quarter, compared to analyst estimates of $122.04 million. Cambrex had a return on equity of 22.20% and a net margin of 22.67%. The company’s quarterly revenue was down 7.1% compared to the same quarter last year. During the same period in the previous year, the company earned $0.55 earnings per share. On average, sell-side analysts forecast that Cambrex Co. will post 2.77 earnings per share for the current fiscal year.

CBM has been the subject of several research analyst reports. TheStreet downgraded Cambrex from a “b” rating to a “c+” rating in a research note on Monday, December 3rd. Zacks Investment Research downgraded Cambrex from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, January 23rd. Robert W. Baird initiated coverage on Cambrex in a research note on Thursday, November 15th. They set an “outperform” rating for the company. ValuEngine raised Cambrex from a “strong sell” rating to a “sell” rating in a research note on Saturday, January 5th. Finally, First Analysis raised Cambrex from an “outperform” rating to a “strong-buy” rating and reduced their target price for the stock from $73.00 to $63.00 in a research note on Friday, November 9th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. Cambrex has a consensus rating of “Buy” and an average price target of $63.17.

WARNING: This article was first posted by Watch List News and is the property of of Watch List News. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at https://www.watchlistnews.com/cwm-llc-has-1-59-million-holdings-in-cambrex-co-cbm/2778819.html.

Cambrex Profile

Cambrex Corp. engages in the provision of products, services, and technologies to accelerate and improve the development and commercialization of new and generic therapeutics. It supplies to innovator and generic pharmaceutical companies. Its products include generic and branded APIs, controlled substances, chiral compounds, high potency APIs, and advanced intermediates.

Featured Article: What are the Benefits of Index Funds?

Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Co. (NYSE:CBM).

Institutional Ownership by Quarter for Cambrex (NYSE:CBM)

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.